REGENHU SA

Their core work

REGENHU is a Swiss SME specializing in 3D bioprinting systems and bioprinter manufacturing. They provide precision bioprinting hardware and expertise to research consortia working on tissue engineering, organ-on-chip platforms, and biofabrication. Across their H2020 portfolio, they consistently serve as the bioprinting technology provider — supplying instruments and process know-how for printing living tissues, biofilms, and microfluidic structures. Their core business is building the machines that make biological 3D printing possible for medical and environmental applications.

What they specialise in

How they've shifted over time

REGENHU entered H2020 in 2019 with an environmental application — 3D-printed biofilms for bioremediation (ELECTRA) — demonstrating the versatility of their bioprinting platform beyond medical use. From 2020 onward, their focus shifted decisively toward biomedical applications: first organ-scale tissue engineering for liver transplantation (ORGANTRANS), then precision organ-on-chip platforms for rheumatoid arthritis drug testing (FLAMIN-GO). This trajectory shows a clear move from broad bioprinting applications toward high-value personalized medicine and clinical testing platforms.

REGENHU is concentrating on precision medicine infrastructure — organ-on-chip and clinical-trial-on-chip — positioning their bioprinting technology as essential equipment for the growing in-vitro testing and personalized therapy market.

How they like to work

REGENHU operates exclusively as a participant, never as coordinator — a pattern consistent with a technology supplier that brings specialized equipment and expertise to research-led consortia. With 42 unique partners across 16 countries in just 3 projects, they work in large, internationally diverse consortia. Their role is that of a specialist contributor: they join where their bioprinting capability is needed, rather than driving the research agenda themselves.

Despite only 3 projects, REGENHU has built a broad network of 42 partners spanning 16 countries, indicating participation in large multi-national consortia. Their reach extends well beyond Switzerland, with connections across Europe and into China (ELECTRA project).

What sets them apart

REGENHU occupies a rare niche as an SME that manufactures 3D bioprinters — the actual hardware instruments — rather than just using them for research. This makes them a critical enabling technology partner: any consortium that needs to bioprint tissues, organs-on-chip, or biological structures benefits from having the equipment maker at the table. Their ability to deploy the same core technology across radically different domains (environmental biofilms, liver organoids, arthritic joint models) demonstrates genuine platform versatility.

Highlights from their portfolio

• ORGANTRANS
  Largest funding share (EUR 1.16M) — focused on organoid transplantation for regenerative medicine, signaling REGENHU's deepest investment in the biomedical bioprinting space.
• FLAMIN-GO
  Represents the frontier of their work: combining 3D bioprinting with microfluidics to build synovia-on-chip models for precision rheumatoid arthritis treatment.
• ELECTRA
  Unusual cross-sector application — using bioprinting for environmental bioremediation with field experiments in China, showing the platform's versatility beyond medicine.